Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Spark Therapeutics options license to UMass gene therapy IP

Executive Summary

In a multi-year collaboration, Spark Therapeutics Inc. and the University of Massachusetts Medical School will work together to identify adeno-associated virus (AAV) vectors with potential application in genetic diseases of the retina, liver, and central nervous system.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register